Intersect ENT, Inc. (NASDAQ:XENT)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $32.30 and last traded at $32.30, with a volume of 107,119 shares trading hands. The stock had previously closed at $31.75.

Several equities analysts have weighed in on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 target price on shares of Intersect ENT in a report on Tuesday, August 22nd. TheStreet upgraded shares of Intersect ENT from a “d” rating to a “c-” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. Finally, Northland Securities reiterated a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a report on Wednesday, August 2nd. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $24.88.

The stock’s 50 day moving average price is $29.70 and its 200-day moving average price is $23.26. The company’s market cap is $926.75 million.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.11. The firm had revenue of $24 million during the quarter, compared to analysts’ expectations of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company’s revenue was up 24.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.21) earnings per share. On average, analysts anticipate that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.

In other news, insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $26.10, for a total transaction of $522,000.00. Following the completion of the transaction, the insider now directly owns 583,493 shares in the company, valued at $15,229,167.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total value of $398,464.65. Following the transaction, the chief financial officer now owns 27,833 shares of the company’s stock, valued at $864,214.65. The disclosure for this sale can be found here. Insiders have sold 133,426 shares of company stock valued at $3,868,685 in the last ninety days. Company insiders own 13.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in shares of Intersect ENT by 0.4% during the first quarter. Wellington Management Group LLP now owns 2,921,012 shares of the medical equipment provider’s stock worth $50,095,000 after buying an additional 10,683 shares during the last quarter. FMR LLC lifted its holdings in shares of Intersect ENT by 247.7% during the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock worth $41,447,000 after buying an additional 1,056,389 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Intersect ENT by 6.7% during the second quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock worth $31,853,000 after buying an additional 71,750 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Intersect ENT by 2,746.9% during the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock worth $26,036,000 after buying an additional 898,785 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in shares of Intersect ENT by 49.8% during the first quarter. Neuberger Berman Group LLC now owns 884,627 shares of the medical equipment provider’s stock worth $15,171,000 after buying an additional 293,949 shares during the last quarter. Institutional investors own 83.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intersect ENT, Inc. (XENT) Hits New 1-Year High at $32.30” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/06/intersect-ent-inc-xent-hits-new-1-year-high-at-32-30.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.